113 related articles for article (PubMed ID: 29333902)
1. Patterns of NPS Use and Risk Reduction in Slovenia.
Sande M; Paš M; Nahtigal K; Šabić S
Subst Use Misuse; 2018 Jul; 53(9):1424-1432. PubMed ID: 29333902
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of the use of 3-MMC and other new psychoactive drugs in Slovenia, and the perceived problems experienced by users.
Sande M
Int J Drug Policy; 2016 Jan; 27():65-73. PubMed ID: 25908121
[TBL] [Abstract][Full Text] [Related]
3. Awareness of users and motivational factors for using new psychoactive substances in Belgium.
Simonis S; Canfyn M; Van Dijck A; Van Havere T; Deconinck E; Blanckaert P; Gremeaux L
Harm Reduct J; 2020 Jul; 17(1):52. PubMed ID: 32711526
[TBL] [Abstract][Full Text] [Related]
4. The diverse reasons for using Novel Psychoactive Substances - A qualitative study of the users' own perspectives.
Soussan C; Andersson M; Kjellgren A
Int J Drug Policy; 2018 Feb; 52():71-78. PubMed ID: 29241144
[TBL] [Abstract][Full Text] [Related]
5. Are government-approved products containing new psychoactive substances perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand.
Rychert M; Wilkins C; Parker K; Witten K
Drug Alcohol Rev; 2018 Mar; 37(3):406-413. PubMed ID: 29285812
[TBL] [Abstract][Full Text] [Related]
6. Exploring the Attractiveness of New Psychoactive Substances (NPS) among Experienced Drug Users.
van Amsterdam JG; Nabben T; Keiman D; Haanschoten G; Korf D
J Psychoactive Drugs; 2015; 47(3):177-81. PubMed ID: 26098724
[TBL] [Abstract][Full Text] [Related]
7. Patterns and correlates of new psychoactive substance use in a sample of Australian high school students.
Champion KE; Teesson M; Newton NC
Drug Alcohol Rev; 2016 May; 35(3):338-44. PubMed ID: 26194894
[TBL] [Abstract][Full Text] [Related]
8. Characterizing users of new psychoactive substances using psychometric scales for risk-related behavior.
Vreeker A; van der Burg BG; van Laar M; Brunt TM
Addict Behav; 2017 Jul; 70():72-78. PubMed ID: 28214739
[TBL] [Abstract][Full Text] [Related]
9. Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.
Palamar JJ; Martins SS; Su MK; Ompad DC
Drug Alcohol Depend; 2015 Nov; 156():112-119. PubMed ID: 26377051
[TBL] [Abstract][Full Text] [Related]
10. Consumption of new psychoactive substances in a Spanish sample of research chemical users.
González D; Ventura M; Caudevilla F; Torrens M; Farre M
Hum Psychopharmacol; 2013 Jul; 28(4):332-40. PubMed ID: 23881881
[TBL] [Abstract][Full Text] [Related]
11. The importance of drug checking outside the context of nightlife in Slovenia.
Sande M; Šabić S
Harm Reduct J; 2018 Jan; 15(1):2. PubMed ID: 29329544
[TBL] [Abstract][Full Text] [Related]
12. Examination of Synthetic Cannabinoid and Cathinone Use among a Drug-Using Offender Sample, 2013-2015.
Smith KE; Bunting AM; Staton M; Walker R; Shalash S; Winston E; Pangburn K
J Psychoactive Drugs; 2017; 49(5):436-445. PubMed ID: 28813207
[TBL] [Abstract][Full Text] [Related]
13. Novel psychoactive substance use by US adolescents: Characteristics associated with use of synthetic cannabinoids and synthetic cathinones.
Patrick ME; O'Malley PM; Kloska DD; Schulenberg JE; Johnston LD; Miech RA; Bachman JG
Drug Alcohol Rev; 2016 Sep; 35(5):586-90. PubMed ID: 26711540
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011-2014.
Palamar JJ; Su MK; Hoffman RS
Am J Drug Alcohol Abuse; 2016; 42(1):39-47. PubMed ID: 26678258
[TBL] [Abstract][Full Text] [Related]
15. Emerging drugs in Europe.
Papaseit E; Farré M; Schifano F; Torrens M
Curr Opin Psychiatry; 2014 Jul; 27(4):243-50. PubMed ID: 24840157
[TBL] [Abstract][Full Text] [Related]
16. New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.
Pirona A; Bo A; Hedrich D; Ferri M; van Gelder N; Giraudon I; Montanari L; Simon R; Mounteney J
Int J Drug Policy; 2017 Feb; 40():84-92. PubMed ID: 27956184
[TBL] [Abstract][Full Text] [Related]
17. Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the Poisons Information Centre.
Hondebrink L; Nugteren-van Lonkhuyzen JJ; Van Der Gouwe D; Brunt TM
Drug Alcohol Depend; 2015 Feb; 147():109-15. PubMed ID: 25541244
[TBL] [Abstract][Full Text] [Related]
18. The rise of new psychoactive substance use in Australia.
Burns L; Roxburgh A; Matthews A; Bruno R; Lenton S; Van Buskirk J
Drug Test Anal; 2014; 6(7-8):846-9. PubMed ID: 24599890
[TBL] [Abstract][Full Text] [Related]
19. Do novel psychoactive substances displace established club drugs, supplement them or act as drugs of initiation? The relationship between mephedrone, ecstasy and cocaine.
Moore K; Dargan PI; Wood DM; Measham F
Eur Addict Res; 2013; 19(5):276-82. PubMed ID: 23615495
[TBL] [Abstract][Full Text] [Related]
20. Drugs of Abuse and Novel Psychoactive Substances at Outdoor Music Festivals in Colorado.
Fox J; Smith A; Yale A; Chow C; Alaswad E; Cushing T; Monte AA
Subst Use Misuse; 2018 Jun; 53(7):1203-1211. PubMed ID: 29148866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
